High frequency of clinically significant mutations after first-line generic highly active antiretroviral therapy failure: implications for second-line options in resource-limited settings.
Continuation of failed highly active antiretroviral therapy regimens can lead to the accumulation of mutations that may limit options for second-line treatment. We studied the pattern of drug resistance mutations among 138 Indian patients who experienced failure of nonnucleotide reverse-transcriptase-containing first-line highly active antiretroviral therapy. This study demonstrates a high frequency of drug resistance mutations in human immunodeficiency virus-infected Indians who experience immunologic treatment failure and suggests the need for viral load monitoring.
Kumarasamy
N
N
YRG Centre for AIDS Research and Education, VHS, Chennai, India. kumarasamy@yrgcare.org
Madhavan
Vidya
V
Venkatesh
Kartik K
KK
Saravanan
S
S
Kantor
Rami
R
Balakrishnan
P
P
Devaleenal
Bella
B
Poongulali
S
S
Yepthomi
Tokugha
T
Solomon
Suniti
S
Mayer
Kenneth H
KH
Benson
Constance
C
Schooley
Robert
R
D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D024882:Drug Resistance, Viral; D005260:Female; D006678:HIV / Q000187:drug effects* / Q000235:genetics; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D008297:Male; D009154:Mutation; D017211:Treatment Failure
D019380:Anti-HIV Agents